InMed Pharmaceuticals (INM) stock surges as the company strikes an all-stock merger deal with migraine drug developer Mentari ...

InMed Pharmaceuticals (INM) shares ripped higher on May 19 as the company announced an all-stock merger with migraine drug ...

InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with ...

The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or ...

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed ...

Detailed price information for Inmed Pharmaceuticals Inc (INM-Q) from The Globe and Mail including charting and trades.

When it comes to treating degenerative diseases like Alzheimer’s, much of the current focus is on addressing the symptoms rather than repairing and regenerating the damaged tissues and cells. Some ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, ...

We’ll send you a myFT Daily Digest email rounding up the latest Paul Connolly news every morning. Independent News & Media has accused Paul Connolly, a non-executive director of the company, of making ...